Finance

Roʻyxatlar
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
278,26 US$
+1,93%
(+5,26) 1K
278,26 US$
0,00% (0,00)
Yopilgandan keyin
Savdolar yopilgan: 11-sen, 16:00:08 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
CRL tikeri uchun statistika yaratilmoqda...
Ochish
276,01 US$
Yuqori
280,40 US$
Past
275,63 US$
Bozor kapitali
13,28 mlrd
Oʻrtacha hajm
903,50 ming
Hajmi
767,56 ming
52 haftalik eng yuqori
303,30 US$
52 haftalik eng past
144,26 US$
Aksiya boʻyicha daromad
-4,85 US$
Beta
1,40
Muomaladagi aksiyalar
47,74 mln
Xodimlar soni
19 ming
Ochish
276,01 US$
Yuqori
280,40 US$
Past
275,63 US$
Bozor kapitali
13,28 mlrd
Oʻrtacha hajm
903,50 ming
Hajmi
767,56 ming
52 haftalik eng yuqori
303,30 US$
52 haftalik eng past
144,26 US$
Aksiya boʻyicha daromad
-4,85 US$
Beta
1,40
Muomaladagi aksiyalar
47,74 mln
Xodimlar soni
19 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
Charles River Laboratories Intrtnl, Inc. haqida
CEO-
Xodimlar soni19 ming
Asos solingan1947
Bosh ofislarWilmington, Massachusetts, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytcriver.com
Analitik reytinglar
Oxirgi 3 oyda CRL aksiyalari boʻyicha reyting bergan 12 tahlilchi xulosasiga koʻra
Sotib olish tavsiya etiladi
Sotib olish
10
Ushlab qolish
2
Sotish
0
12 oylik prognoz
Oxirgi 3 oyda CRL uchun 12 oylik narx maqsadlarini taklif qilgan 12 Wall Street tahlilchisi xulosasiga koʻra
Eng yuqori
Joriy 278,26 US$
320,00 US$ (+15,00%)
O‘rtacha
286,45 US$ (+2,94%)
Eng past
219,00 US$ (-21,30%)
Analitik
Tavsiya
Amal
Kutilayotgan narx
Prognoz
Sana
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
320,00 US$
+15%
09/11/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
264,00 US$
-5,1%
08/10/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
300,00 US$
+7,8%
08/10/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
300,00 US$
+7,8%
08/06/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
291,00 US$
+4,6%
08/06/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
300,00 US$
+7,8%
08/06/2026
Ryan Halsted
RBC Capital
Buy
Maintained
282,00 US$
+1,3%
08/05/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
310,00 US$
+11,4%
08/05/2026
Luke Sergott
Barclays
Buy
Maintained
300,00 US$
+7,8%
08/05/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
219,00 US$
-21,3%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
265,00 US$
-4,8%
07/08/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
-
-
06/05/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
David Windley
Jefferies
Buy
Maintained
225,00 US$
-19,1%
05/08/2026
Charles Weston
RBC Capital
Buy
Initiated
215,00 US$
-22,7%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
175,00 US$
-37,1%
02/25/2026
Oxirgi hisobot
5-avg, 2026
Moliya davri
Ch.2 2026
Aksiya boʻyicha taxminiy daromad (USD)
3,02 US$ / 2,73 US$
+10,65%musbat
Taxminiy daromad (USD)
1,00 mlrd / 977,20 mln
+2,75%musbat
Q2 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad hisoboti
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
1,00 mlrd
994,23 mln
995,83 mln
1,00 mlrd
Sotilgan mahsulotning tannarxi
652,72 mln
665,36 mln
672,79 mln
625,06 mln
Daromad narxi
652,72 mln
665,36 mln
672,79 mln
625,06 mln
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
173,64 mln
192,02 mln
149,12 mln
214,18 mln
Operatsion xarajatlar
201,05 mln
284,04 mln
164,46 mln
227,27 mln
Jami operatsion xarajatlar
853,77 mln
949,40 mln
837,25 mln
852,33 mln
Operatsion daromad
151,08 mln
44,83 mln
158,58 mln
151,74 mln
Boshqa nooperatsion daromad
-22,62 mln
27,72 mln
-123,11 mln
25,99 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
87,20 mln
-294,10 mln
-29,94 mln
53,17 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
104,48 mln
35,18 mln
8,62 mln
148,43 mln
Daromad soligʻi boʻyicha xarajat
31,64 mln
-17,81 mln
-15,14 mln
53,93 mln
Amaldagi soliq stavkasi
36,29%
6,06%
50,56%
101,43%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
54,42 mln
-276,56 mln
-14,84 mln
-1,48 mln
Sof foyda marjasi
5,42%
-27,82%
-1,49%
-0,15%
Har bir aksiya foydasi
2,43
2,39
2,06
3,02
Foizlar va investitsiyalardan olingan daromadlar
1,42 mln
1,02 mln
1,03 mln
1,03 mln
Foizlarni toʻlash xarajatlari
-25,40 mln
-23,78 mln
-26,74 mln
-30,34 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-23,98 mln
-22,76 mln
-25,71 mln
-29,31 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
236,25 mln
169,61 mln
225,73 mln
217,54 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
117,98 mln
24,92 mln
Insayder tranzaksiyalari
Insayder tranzaksiyalari maʼlumotlari tashqi manbalardan olingan. Batafsil
Insayder
Joylashuvi
Turi
Sana
Aksiyalar
Miqdor
1-sahifa
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari